IRWDIRONWOOD PHARMACEUTICALS INC
Pharmaceutical Preparations
- Revenue
- $296M
- 16% YoY
- Operating margin
- 33.3%
- 26% YoY
- EBITDA
- $100M
- 5.6% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 1.2×
- $120M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear529% of net incomeCash flow under 80% of net income
- Dilutive SBCClear6% of revenueOver 10% of revenue
- Payouts exceed cash flowClear99% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $414M | $411M | $443M | $351M | $296M | 16% |
| Operating income | $232M | $250M | −$945M | $93M | $99M | 5.8% |
| Net income | $528M | $175M | −$1.0B | $880K | $24M | 2630% |
| Operating cash flow | $262M | $274M | $183M | $104M | $127M | 23% |
| Capex | $265K | $136K | $273K | $142K | $34K | 76% |
| Stock-based comp | $22M | $27M | $32M | $30M | $17M | 42% |
| Buybacks | $24M | $126M | — | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $1M | 27 | — |
| FY2024 | $6M | −$4M | 36 | — |
| FY2023 | $8M | $5M | 92 | — |